SYSTEMATIC REVIEW OF CYTOTOXIC THERAPY

Fossati and colleagues (2009) performed a systematic review of randomized clinical trials in metastatic breast cancer reported between 1975 and 2009 that were identified by a MEDLINE and EMBASE search. The data extracted from each report included tumor response, the hazard ratio for mortality, and proportion of patients with severe side effects. A total of 189 randomized trials was identified, of which all provided response data and 133 (70%) provided data or Kaplan-Meier curves necessary for calculation of the hazard ratios. A total of 165 were two-arm trials, and 24 studies included three or more arms. The trials were categorized into twelve separate groups by their primary comparison, in­cluding six groups that included chemotherapy as a component of therapy :

Polychemotherapy versus single agent therapy: Polychemotherapy was associated with a higher objective response rate (48 versus 34%) and a significant reduction in the hazard rate for death whether the comparison was anthracycline combinations versus single-agent anthracyclines (HR 0.87; 95%), or nonanthracycline combinations versus single agents (HR 0.70; 95%).

Anthracycline versus nonanthracycline chemotherapy: Anthracyclines were associated with a significantly higher response rate (51 versus 45%) but had no significant effect on survival. Anthracyclines produced more nausea and vomiting, leukopenia, alopecia, and neurological and cardiac toxicity. There was a modest reduction rate in the hazard rate for death (HR0.89; 95%) if the comparison regimen did not contain predni­sone, whereas there was a disadvantage for anthracyclines (HR 1.16; 95%) when compared with a regimen that contained prednisone.

Other chemotherapy versus CMF: There was a slightly higher response rate for the non-CMF regimens (49 versus 44%), but the non-CMF regimens produced significantly more nausea and vomiting, leukopenia, alopecia, and neurological toxicity. There was no significant difference in the hazard rate for death.

Epirubicin versus doxorubicin: There was no significant difference in response rate (44 versus 47%). Epirubicin produced less leukopenia and cardiac toxicity. Epirubicin was associated with a trend toward a higher risk for death (HR 1.13; 95%), although this was not statistically significant.

Standard-dose versus low-dose chemotherapy: Standard-dose chemotherapy was asso­ciated with a significantly higher response rate (44 versus 33%) but also with more nausea and vomiting, leukopenia, mucositis, and alopecia. Standard-dose therapy was associated with a significant reduction in the hazard rate for death (HR 0.90; 95%).

Chemotherapy versus chemohormonal therapy: Hormonal therapy consisted of ta­moxifen, medroxyprogesterone acetate, estrogen, oophorectomy, and other hormones. There was a higher response rate for chemohormonal therapy (56 versus 46%) but also a higher risk of cardiac toxicity, hot flashes, and edema. There was no significant effect on the hazard rate for death.

One thought on “SYSTEMATIC REVIEW OF CYTOTOXIC THERAPY”

Bir Cevap Yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir